Catalyst Biosciences Awarded EU Patent for Experimental Hemophilia B Therapies
Catalyst Biosciences has received a European Union patent for its investigational hemophilia B treatments, including its lead therapy candidate, dalcinonacog alfa (DalcA) and a preclinical gene therapy candidate called CB…